Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Operating Leases (2019 - 2025)

Niagen Bioscience (NAGE) has disclosed Operating Leases for 7 consecutive years, with $1.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Leases fell 30.19% to $1.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.8 million, a 30.19% decrease, with the full-year FY2025 number at $1.8 million, down 30.19% from a year prior.
  • Operating Leases was $1.8 million for Q4 2025 at Niagen Bioscience, down from $3.1 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $4.7 million in Q4 2021 to a low of $1.4 million in Q1 2021.
  • A 5-year average of $3.3 million and a median of $3.3 million in 2021 define the central range for Operating Leases.
  • Peak YoY movement for Operating Leases: surged 477.97% in 2021, then plummeted 50.25% in 2024.
  • Niagen Bioscience's Operating Leases stood at $4.7 million in 2021, then dropped by 10.64% to $4.2 million in 2022, then crashed by 38.98% to $2.6 million in 2023, then grew by 1.44% to $2.6 million in 2024, then plummeted by 30.19% to $1.8 million in 2025.
  • Per Business Quant, the three most recent readings for NAGE's Operating Leases are $1.8 million (Q4 2025), $3.1 million (Q3 2025), and $3.3 million (Q2 2025).